BeOne Medicines Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
246.68
+6.27 (2.61%)
At close: May 29, 2025, 4:00 PM
241.89
-4.79 (-1.94%)
After-hours: May 29, 2025, 4:08 PM EDT
BeOne Medicines Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for BeOne Medicines stock ranges from a low of $311 to a high of $350. The average analyst price target of $326.43 forecasts a 32.33% increase in the stock price over the next year.
Price Target: $326.43 (+32.33%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BeOne Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|
| Strong Buy | 0 | 2 | 2 |
| Buy | 2 | 5 | 5 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 2 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $312 → $311 | Buy | Maintains | $312 → $311 | +26.07% | May 8, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $348 → $350 | Strong Buy | Maintains | $348 → $350 | +41.88% | May 8, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $312 | Buy | Reiterates | $312 | +26.48% | Apr 28, 2025 |
| TD Securities | TD Securities | Strong Buy Reiterates $334 | Strong Buy | Reiterates | $334 | +35.40% | Apr 24, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $311 → $317 | Buy | Maintains | $311 → $317 | +28.51% | Apr 21, 2025 |
Financial Forecast
Revenue This Year
36.93B
from 27.81B
Increased by 32.78%
Revenue Next Year
43.97B
from 36.93B
Increased by 19.07%
EPS This Year
0.35
from -44.70
EPS Next Year
2.58
from 0.35
Increased by 641.69%
Financial currency is CNY. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 39.2B | 48.9B | 56.0B | ||
| Avg | 36.9B | 44.0B | 50.1B | ||
| Low | 35.1B | 37.7B | 43.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 41.1% | 32.5% | 27.4% | ||
| Avg | 32.8% | 19.1% | 14.0% | ||
| Low | 26.2% | 2.2% | -0.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.91 | 3.69 | 5.71 | ||
| Avg | 0.35 | 2.58 | 5.24 | ||
| Low | 0.10 | 1.57 | 4.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 960.5% | 121.3% | ||
| Avg | - | 641.7% | 103.3% | ||
| Low | - | 351.0% | 83.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.